8-K: SELLAS Life Sciences Announces Positive Phase 3 Trial Outcome and Full Year 2024 Financial Results

SELLAS Life Sciences reports positive interim analysis for its Phase 3 REGAL trial in AML and provides a corporate update, including full year 2024 financial results.

Summary

• SELLAS Life Sciences Group announced positive results from the interim analysis of its Phase 3 REGAL trial for Galinpepimut-S (GPS) in acute myeloid leukemia (AML).
• The company anticipates the final analysis of the REGAL trial in 2025 upon reaching 80 events (deaths).
• Positive overall survival and overall response rate data were reported from the ongoing Phase 2 trial of SLS009 (Tambiciclib) in r/r AML, with full data and FDA regulatory path feedback expected in the first half of 2025.
• In the Phase 2 trial of SLS009, a 56% overall response rate (ORR) was observed in AML patients with myelodysplasia-related changes (AML MRC), exceeding the pre-specified target ORR of 33%.
• In the optimal dosing regimen of 30 mg BIW, the median overall survival (mOS) has not been reached but exceeds 7.7 months at the latest follow-up, where the expected mOS is historically approximately 2.5 months.
• SELLAS raised $25 million in gross proceeds through a registered direct offering in January 2025.
• Research and development expenses for 2024 were $19.1 million, compared to $24.0 million in 2023.
• General and administrative expenses for 2024 were $12.4 million, compared to $13.9 million in 2023.
• The net loss for 2024 was $30.9 million, or $0.50 per share, compared to a net loss of $37.3 million, or $1.34 per share, in 2023.
• As of December 31, 2024, cash and cash equivalents totaled approximately $13.9 million.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with promising clinical trial results and regulatory designations, although the company is still loss-making. The recent capital raise provides financial stability.

Positives

• Positive interim results from the Phase 3 REGAL trial suggest potential efficacy of GPS in treating AML.
• The Phase 2 trial of SLS009 shows promising results with a high overall response rate and extended overall survival in AML patients.
• Multiple regulatory designations received in 2024 may accelerate development and potential approval of SELLAS' therapies.
• The $25 million capital raise strengthens the company's financial position.
• The overall response rate (ORR) of 67% in the Phase 2a trial of SLS009 in combination with Zanubrutinib in DLBCL, more than double the expected ORR of zanubrutinib alone.

Negatives

• The company reported a net loss of $30.9 million for the year ended December 31, 2024.
• Cash and cash equivalents totaled approximately $13.9 million as of December 31, 2024, which may require additional funding in the future.

Risks

• The final analysis of the Phase 3 REGAL trial is dependent on reaching 80 events (deaths), which may be subject to unforeseen delays.
• The development and clinical success of oncology products are inherently uncertain.
• Regulatory approval is not guaranteed and is subject to review and potential rejection by regulatory agencies.
• The company's financial position may require additional funding to support ongoing clinical trials and operations.

Future Outlook

The company anticipates the final analysis of its Phase 3 REGAL trial in 2025 and expects full topline Phase 2 data of SLS009 in AML in the first half of 2025, both of which represent significant opportunities for regulatory approval and potential transformative treatments for AML patients.

Management Comments

• We are pleased with the progress of our pipeline as we continue to advance our two key assets through clinical development, said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS.
• If successful, the REGAL trial provides a pathway for regulatory approval in AML, and GPS could become a transformative treatment for patients in their second complete remission.
• We are especially encouraged by the multiple regulatory designations granted to our programs in 2024, which reflect the significant potential impact of our therapies and provide valuable regulatory benefits that may accelerate development and potential approval.
• With strong regulatory recognition and two potentially pivotal inflection points ahead, we remain committed to driving innovation and delivering value to patients and shareholders.

Industry Context

SELLAS is operating in the competitive biopharmaceutical industry, focusing on novel therapies for cancer indications, particularly AML. The positive results from the REGAL trial and SLS009 trials position the company to potentially address unmet needs in the treatment of AML and other hematologic malignancies.

Comparison to Industry Standards

• The reported median overall survival (mOS) exceeding 7.7 months in the SLS009 trial, compared to a historical mOS of approximately 2.5 months, suggests a significant improvement over existing treatments.
• The 56% overall response rate (ORR) in AML patients with myelodysplasia-related changes (AML MRC) in the SLS009 trial, exceeding the pre-specified target ORR of 33%, indicates a potentially competitive efficacy profile.
• The 67% overall response rate (ORR) in the Phase 2a trial of SLS009 in combination with Zanubrutinib in DLBCL, more than double the expected ORR of zanubrutinib alone, suggests a potentially competitive efficacy profile.

Stakeholder Impact

• Positive clinical trial results and potential regulatory approvals could benefit shareholders through increased stock value.
• Successful development of new therapies could improve treatment options and outcomes for cancer patients.
• The company's financial stability and growth potential could provide job security and opportunities for employees.

Next Steps

• Conduct the final analysis of the Phase 3 REGAL trial of GPS in AML upon reaching 80 events (deaths).
• Release full topline Phase 2 data of SLS009 in AML and seek FDA regulatory path feedback in the first half of 2025.
• Determine next steps in development around lymphoma with GenFleet Therapeutics (Shanghai), Inc.

Key Dates

Keywords

SELLAS Life Sciences, Galinpepimut-S, GPS, SLS009, Tambiciclib, AML, Acute Myeloid Leukemia, REGAL Trial, Clinical Trial, FDA, EMA, Regulatory Approval, Oncology, Biopharmaceutical, Financial Results